Beta Drugs News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Beta Drugs Ltd. authored by Edelweiss and published by - Trendlyne research reports.
Item: Beta Drugs Ltd.
Rating: 5
Author: Edelweiss

Keep track of all breaking news and updates on Beta Drugs from all sources in a single place.

Beta Drugs Ltd.

21 Nov 2025

1642.90

1.44%

Beta Drugs up 3% on approval to migrate shares from SME to mainboard

Business Standard

The buying on the counter came after the company received the approval for listing its equity shares on the Capital Market Segment (Main Board) from SME Emerge platform (NSE)

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

22 Mar 2025

1642.90

1.44%

Bonus shares: THESE three stocks to trade ex-bonus next week (Beta Drugs, Dhanalaxmi Roto Spinners, and KBC Global)

livemint

Bonus shares: Here are three stocks to trade ex-bonus next week ' These include Beta Drugs, Dhanalaxmi Roto Spinners, and KBC Global)

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

27 Nov 2024

1642.90

1.44%

Healthquad Fund II Invests Rs 117 Crore In Beta Drugs For Minority Stake

NDTV Profit

The company will use the newly raised funds to accelerate its growth and aspires to be among the top five oncology companies in India.

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

08 Nov 2024

1642.90

1.44%

Beta Drugs | H1FY25 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Strong show in H1; near-term growth factored in

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

07 Nov 2024

1642.90

1.44%

Beta Drugs Results Earnings Call for Q2FY25

Conference Call with Beta Drugs Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.

Beta Drugs Ltd.

16 May 2024

1642.90

1.44%

Beta Drugs Ltd | H2FY24 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Deepening its roots in the market

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

15 May 2024

1642.90

1.44%

Beta Drugs Results Earnings Call for Q4FY24

Conference Call with Beta Drugs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Beta Drugs Ltd.

03 Sep 2023

1642.90

1.44%

Beta Drugs | The CUB Series

Buy: Beta Drugs Ltd.

Edelweiss

Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market.

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

24 Mar 2023

1642.90

1.44%

Beta Drugs | Plant Visit Note

Not Rated: Beta Drugs Ltd.

Edelweiss

We visited Beta Drugs' (BETADR) formulation facilities located at Baddi and Mohali (Chandigarh), which have been expanded and upgraded, and the management.

Beta Drugs Ltd. is trading below all available SMAs

Beta Drugs Ltd.

07 Dec 2021

1642.90

1.44%

Business Update: Beta Drugs

Conference Call with Beta Drugs Management and Analysts on recent Business Updates. Listen to the full transcript.

Is Beta Drugs Ltd. worth buying?

66 Votes:

Buy 78.79%

Sell 12.12%

Hold 9.09%